Recent research work characterizing the phenotype and immune checkpoint receptor expression on CD4+ and CD8+ T cells from AML patients after the first and second cycles of HMA/VEN found an increase in naïve CD8+ T cells and TIM-3+, CD4+, and CD8+ T cells, along with a reduction in cytokine-secreting non-suppressive T regulatory cells (Tregs) [25]. This evidence concerns the gene CD4 and acute myeloid leukemia.